Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Omega Research Consultants

Neither a doctor nor a teaching hospital

Research payments

$6,235,160

252 payments

Through program year 2025, Omega Research Consultants is reported as receiving $6,235,160 in research payments, across 252 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,508,267 13
2024 Research $1,530,309 11
2023 Research $729,360 14
2022 Research $21,086 17
2021 Research $85,264 30
2020 Research $95,771 64
2019 Research $265,102 103

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca UK Limited $3,660,454 18 payments
  2. E.R. Squibb & Sons, L.L.C. $1,413,572 8 payments
  3. AstraZeneca Pharmaceuticals LP $373,230 6 payments
  4. AstraZeneca AB $317,751 1 payment
  5. AbbVie, Inc. $296,086 181 payments
  6. GlaxoSmithKline, LLC. $86,190 23 payments
  7. Incyte Corporation $31,029 5 payments
  8. Sanofi US Services Inc. $21,600 1 payment
  9. Celgene Corporation $20,449 7 payments
  10. ViiV Healthcare Company $7,800 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Single Dose Non-Randomised Open-Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2693 $1,262,813 4 payments
  2. A Phase I Open Label Single Dose Non Randomised Parallel Group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics Safety and Tolerability of AZD6234 $1,049,259 2 payments
  3. A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment $711,990 2 payments
  4. A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis $690,354 1 payment
  5. A Phase I Single-Dose Non-Randomised Open-Label Parallel-Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics Safety and Tolerability of AZD0780 $464,205 3 payments
  6. Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) $440,841 1 payment
  7. A SingleDose NonRandomised OpenLabel ParallelGroup Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics Safety and Tolerability of Opemalirsen AZD2373 $439,577 1 payment
  8. A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004 $323,265 2 payments
  9. Phase I Single Dose,Non Randomised,Ope NLabel,Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics,Safety and Tolerability of Mitiperstat $171,237 3 payments
  10. M14-702 $92,621 32 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record